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ABSTRACT: A panel of aggregate data for 50 provinces is used to analyze Spain’s 
per capita public pharmaceutical expenditures. In contrast to previous practice, 
our approach permits the analysis of the effects determinants on pharmaceutical 
expenditure to be heterogeneous across years and provinces. Considerable 
parametric heterogeneity over time as well as across provinces is found, even 
after controlling for residual temporal heterogeneity and interdependence as well 
as residual spatial spillovers. This underlines the need for using disaggregate 
spatial data when attempting to model macroeconomic behavior. 
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1. INTRODUCTION 
During the last decade, public pharmaceutical expenditures in Spain have grown faster 
than total public health care spending (Darbá 2003a; Darbá, 2003b). Thus, public pharmaceutical 
expenditure makes up an increasing share of total public health care spending. Pharmaceutical 
expenditure made up 16.8 percent in 1991 and had by 2002 increased to make up 23 percent of 
Spain’s total health care spending (Lopez-Casanovas et al., 2005). This growth is found not only 
in Spain, but is a general feature of the European Union (Ess et al., 2003). Nonetheless, Spanish 
pharmaceutical expenditures as a share of public health care spending exceed the European 
Union’s, raising questions about the causes of this rapid growth  (Lopez-Casanovas, 2005). 
The regulation of the pharmaceutical market in Spain is shared between national 
regulatory bodies and the regional authorities. There are notable differences in health resources 
supply and health care expenditure across regions (Lopez-Casanovas et al., 2005). There also is 
evidence of regional variation in prescription rates and expenditure per prescription resulting in 
regional heterogeneity in pharmaceutical expenditure and in the pharmaceutical expenditure as a 
share of the total regional health care expenditure (Costa-Font and Puig-Junoy, 2004). 
Studies on pharmaceutical expenditure from the regional perspective are scant, though it 
is possible to find a few works dealing with the analysis of regional health care expenditure 
(Lopez-Casasnovas and Saez, 2001; Kitchener et al., 2003; Levaggi and Zanola, 2003; Moscone 
and Knapp, 2005). Despite an ample body of evidence in the literature on variations in the use of 
procedures at the local level (Wennberg and Gittelsohn, 1973; Ham, 1988; Folland et al., 2003; 
Joines et al., 2003; Westert et al., 2004), few studies have examined the geographical variability 
in the consumption of pharmaceuticals (Metge et al., 1999; Dubois et al., 2002; Morgan, 2005). 
The causes of variation discussed in the literature include regional differences in the prevalence 
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of diseases, opinions regarding the effectiveness of surgery, medical practice style, the supply of 
health resource, and patient preferences. 
Only a few studies of small-area variation have considered spatial variation in medical 
practice. One studied spatial disparities in hospital discharges (measured by coefficients of 
variation) and found these disparities to be relatively unchanged during the 1980s and 1990s 
(Westert et al., 2004). Another study by Joines et al. (2003) found that hospitalization rates for 
lower back problems varied significantly across counties of North Carolina. They further found 
that counties with similar rates were geographically clustered and concluded that spatial effects 
are important and should be considered in small-area studies. A third study by Moscone and 
Knapp (2005) explored the spatial patterns of mental health expenditure and established, similar 
to Joines et al. (2003), the importance of controlling for spatial spillovers. This study found a 
positive significant spatial effect suggesting that adjacent local authorities mimic the behavior of 
their neighbors and tend to have similar mental health expenditure. 
The present study focuses on provincial variations in the determinants of public 
pharmaceutical expenditure in Spain and aims to contribute to the literature on small-area 
variation in the determinants of health care expenditures. Specifically, we suggest integrating 
three modeling features. First, parametric heterogeneity is captured by specifying a model that 
includes a time trend and geographical coordinates of the provinces. Second, in order to obtain 
efficient results, a seemingly unrelated regression (SUR) framework is applied to capture  
intertemporal residual correlation and time-varying residual variances. Finally, residual spatial 
spillovers are controlled for by specifying spatially autocorrelated (SAC) residuals. We conclude 
that the effects of determinants vary substantially across time as well as across provinces, and 
that potentially misleading conclusions regarding the effects of key determinants like GDP and 
health system characteristics can occur if simpler specifications are applied. 
2. THE SPANISH PHARMACEUTICAL MARKET 
In Spain, the prices of publicly financed pharmaceuticals are fully or partially controlled, 
and the real price of medicines has not risen much in the last decade. Nevertheless, this does not 
preclude new products from entering the market at prices that are higher than those of existing 
ones. Several studies have shown that the replacement of older drugs by newer, more expensive, 
drugs is the single most important cause of increases in pharmaceutical expenditures (Dubois et 
al., 2000; Gerdtham and Lundin, 2004; Morgan, 2005); real prices of existing drugs are actually 
decreasing. The second most important cause is that larger quantities are consumed because of 
increases in the intensity of medication, defined in terms of daily dose per patient. Similar results 
are found for Spain in analyses of nationwide increases in pharmaceutical expenditures (Rovira 
et al., 2001; Darbá, 2003b). 
The Spanish national health system is decentralized. The regulation of the pharmaceutical 
market is shared between national regulatory bodies and the regional authorities – called 
Autonomous Communities (AC). Most of the key regulatory bodies, however, are run centrally 
at the national level. This reduces diversity and helps maintain overall cost control (Costa-Font 
and Puig-Junoy, 2004). See Figure 1 for a map of provinces by AC.  
Even though cost containment has been a major priority for publicly financed 
pharmaceuticals, it has not significantly curbed public spending (Darbá, 2003a; Darbá, 2003b; 
Costa-Font and Puig-Junoy, 2004). Average prices for pharmaceuticals in Spain are relatively 
low. Spain, of course, does consume some older (many generic) drugs that are priced 
significantly below the EU average (Puig-Junoy, 2004).   In 2000, however, the market share for  
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FIGURE 1.  Provinces with Autonomous Communities Shown 
 
 
generic drugs in Spain was surprisingly lower than that in the EU overall. But the share has been 
rising. It accounted for 3 percent of the Spanish drug sales in 2000 and increased to 6.4 percent 
by 2003 (Costa-Font and Puig-Junoy, 2004). Moreover, there seems to be significant regional 
heterogeneity in the use of generics in Spain (Costa-Font and Puig-Junoy, 2004). New drugs own 
a disproportionate share of the pharmaceutical market in Spain (Darbá, 2003a; Darbá, 2003b; 
Costa-Font and Puig-Junoy, 2004). Combined, this suggests that in Spain newer drugs are priced 
modestly below the EU average. 
Various cost containment policies such as negative lists of excluded drugs, regulation of 
profits, repayments from pharmaceutical companies, reference pricing system and promotion of 
generic drugs have had little effect on the overall increase in pharmaceutical expenditure. Some 
of these policies are under the devolved responsibility of the 17 regional health systems. The 
ACs gradually became significant actors in pharmaceutical policy, starting in the early 1980s and 
fully formed with the completion of the devolution process in 2002. 
Funding is mainly centrally collected and distributed to the ACs. Until 2001, regional 
health care financing was decided in a separate negotiation between the Minister of Health and 
the corresponding Regional Ministers in the 17 ACs, mainly as block grants following the lines 
of an unadjusted capitation formula (Lopez-Casasnovas, Costa-Font, and Planas, 2005). Since 
2002, health care expenditures have been allocated as part of the general financing using a 
capitation formula with some demographic adjustments. Health care expenditures account for 
around 40 percent of the ACs’ total funding. The ACs can change health care funding through 
their own tax structures, but various forms of central funds are applied to maintain interregional 
equity. Some interregional inequalities remain in health expenditure per capita, but the 
coefficient of variation in regional health care expenditure per capita is one of the lowest among 
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health care systems for which territorial health care expenditure may be identified (Lopez-
Casanovas and Saez, 2001). 
There seem to be significant regional differences in hospital specialization, physician 
density and available medical technology. It has been suggested that this diversity can be 
explained partly by differences in a particular region’s GDP contributions and demographic 
compositions (Lopez-Casasnovas, Costa-Font, and Planas, 2005). Interestingly, regional 
inequality in health expenditure is not correlated with inequality in health outcomes (Lopez-
Casasnovas, Costa-Font, and Planas, 2005). There is, however, evidence of significant regional 
variation in prescription rates and expenditure per prescription resulting in significant regional 
heterogeneity in pharmaceutical expenditure as a share of the total regional health care 
expenditure (Costa-Font and Puig-Junoy 2004). 
3. METHODOLOGY 
Assuming a cross-section of N = 50 provinces, a basic homoskedastic linear regression 
model can be written as: 
(1) ,ttt Xy    ),0(~ 2 INt  , 
where tX  is an N by K dimensional matrix of explanatory variables, ty  is an N dimensional 
vector of endogenous observations,   is a K dimensional vector of coefficients, and t  is a 
residual with variance 2 .  
A restrictive assumption of the model expressed in equation (1) is that   is constant 
over time and across provinces. Actually, this is a precondition for t  to remain homoskedastic. 
To allow the   coefficients to vary across time and provinces, we apply expansions (Jones and 
Casetti, 1992; Casetti, 1997). The effect of the kth regressor (k = 0 ,.., K, with the convention that 
0  is the constant term, i.e., 10 X ) is specified as: 
(2) 2 22 20k k Tk Hk Vk HVkH k V kT H H V V HV              , 
where jk  (j=T, H, H2, V, V2, HV) are coefficients, T is a time trend, and H and V are the 
horizontal (west to east) and vertical (south to north) coordinates of the geographical midpoints 
of the regions respectively, The square terms H2 and V2 together with the interaction term HV is 
inserted to allow for non-linear and diagonal dispersion of the   coefficients. Inserting (2) in (1) 
gives the expanded specification: 
(3) 

 K
k
tkTktkkt TXXY
0
0 )({
 ttkHVktkkVtkVktkkHtkHk HVXXVVXXHHX  )}()()()()( 22 22 . 
 Operationally, expanded specification (3) can be estimated by applying multiplicative 
interaction terms between kX  and the T, H, V, and HV variables. Next, the k  coefficients for 
each province by each time period, say kit , can be calculated from (2) together with their 
standard errors, as the   parameters are simple linear functions of the   parameters. Finally, 
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the average for each time period and the average for each region are readily obtained to serve 
illustrative and interpretational purposes. 
Furthermore, one should be aware of the potential sensitivity of the jk  parameters and 
their t values to collinearity caused by the inclusion of the interaction terms in (3). However, 
their linear combinations (i.e., the kit parameters) and their t values do not share this sensitivity. 
Thus, interpretation of the results should be based on the kit parameters rather than the jk  
parameters. 
In order to obtain efficient estimation results, the structure of the residuals needs 
consideration. First, to account for residual spatial spillovers, the spatially autocorrelated (SAC) 
specification (Anselin, 1988) is applied to the residual of (3), that is: 
(4) ttt W  ,  
where   is an autocorrelation parameter and W an N  N contiguity matrix defined by letting wij 
equal 1 in  if provinces i and j are neighbors  (ij) and 0 otherwise, as ni is the number of 
neighbors to province i. Intuitively, the product tW  defines a variable for each province that is 
the average t  of neighboring provinces. Next, when applying pooled data for T periods, the 
residuals are temporally correlated and the variances for the cross sections fluctuate with time. 
Thus, between any two points in time, the residual covariance of t  is specified as: 
(5) 2)'( tsstE  ,  Tst ,..,1,  . 
The model defined by (3), (4), and (5) is estimated efficiently by applying the following 
maximum likelihood approach. We performed a grid search of the relevant values of   from -1 
to +1. Conditioned on each  , a feasible generalized least squares (F-GLS) estimation (Zellner 
1962) is applied to (3) using ( ) tI W y  instead of ty  and ( ) tI W X  instead of tX  to obtain 
SUR estimates of  . Finally, the set of results which maximized the log likelihood function are 
selected. For well-behaved data, this procedure produces results similar to those of the traditional 
maximum likelihood estimation. For ill-behaved data, however, traditional maximum likelihood 
estimation may lead to suboptimal estimates due to attainment only of local optima. While the 
grid search procedure is slightly more time consuming, it is less disposed to attaining local 
optima as opposed to the global one.  
To compare alternative models, the pseudo-R2 and the Akaike information criterion 
(AIC) are used. Wald tests for the expansions also are provided, i.e., for the hypotheses that T  
and/or  2 2, , , ,H V HVH V     equal 0. 
4. DATA 
Data for 50 Spanish provinces were collected. These provinces correspond with the 
NUT-3 level of aggregation according to EUROSTAT (excluding the autonomous cities of Ceuta 
and Melilla). The provinces are grouped into 17 Autonomous Communities (AC). The ACs 
correspond with the NUT-2 level of aggregation according to EUROSTAT. They present a 
higher degree of heterogeneity than do the provinces. Regarding the decentralization process, 
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seven of the ACs had independent responsibilities during the 1980s and 1990s, while the last 10 
took on responsibility for health care regulation in 2002.  
The data were collected annually from 1996 to 2003 from two sources, the National 
Statistical Institute (INE) and the Ministry of Health and Consumption (MSC). The dependent 
variable is public pharmaceutical expenditure per capita (EXP). It includes expenditures on 
extra-hospital drugs managed by the administration, but does not take private purchases into 
account. To capture the influence of wealth, GDP per capita (GDP) is included as an explanatory 
variable. Further, to capture influences of the health care system, the number of pharmacists per 
1000 inhabitants (PHARM), number of hospital beds per 1000 inhabitants (BEDS), and number 
of medical doctors per 1000 inhabitants (MED) are included. Finally, to capture the influence of 
the composition of the population, the share of population that is female (FEM), foreigners 
(FOREIGN), people over 65 years (OLD), and 0 to 4 year old children (CHILD) are included. 
Table 1 presents the data applied, including means and standard deviations (average over eight 
years). 
The variables describing the population control for socio-demographic risk factors and 
are considered to be proxies for need, whereas GDP controls for ability to pay. The variables 
describing the health care system do not solely reflect supply factors but are a result of 
interactions between demand and supply factors. Some health system variables may be 
considered to be substitutes for the utilization of pharmaceuticals while others are 
complementary. A priori, one would expect the number of pharmacists to be complementary 
whereas we have no unambiguous a priori hypothesis for hospital beds and medical doctors. 
 
TABLE 1. Variables Used in the Analysis 
Variable Description Source Mean Std. D. 
EXP Pharmaceutical Expenditure 
per capita  
MSC, Institute of 
Sanitary Information 
164.899 31.710
GDP GDP per capita  INE, National 
Statistical Institute 
9241.57 1766.14
PHARM Pharmacists per 1000 
inhabitants 
INE, Social Indicators, 
2004 
1.206 0.225
BEDS Hospital beds per 1000 
inhabitants 
MSC, National Hospital 
Catalogue 
0.004 0.001
MED Medical doctors per 1000 
inhabitants 
INE, Social Indicators, 
2004 
4.183 0.739
FEM Share of population female INE,National Statistical 
Institute 
0.506 0.006
FOREIGN Share of population foreign INE, National 
Statistical Institute 
0.018 0.019
OLD Share of population over 65 
years 
INE, National 
Statistical Institute 
0.185 0.042
CHILD Share of population 
between 0 to 4 years 
INE, National 
Statistical Institute 
0.090 0.016
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FIGURE 2. Variables by Provinces  
(darker tones indicate larger magnitudes) 
          EXP              GDP                  PHARM 
       BEDS     MED                                            FEM 
       BEDS                  OLD           CHILD 
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FIGURE 3. Student t-Values of Coefficients by Provinces (averaged over eight years) 
               Constant                                       GDP                                          PHARM 
                  BEDS        MED         FEM 
                FOREIGN                                     OLDS                                          CHILD 
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Figure 2 shows the distribution of variables (averaged over eight years) by province. 
Spatial patterns are predominant, though not of a unique nature. For the expenditure, a clear 
indication of spatial spillover is seen. Comparing the maps in Figure 2 to the map of ACs in 
Figure 1, this spillover seems to be of an intra- as well as a supra-AC nature. Further, there 
seems to be some tendencies to north/west-south/east contrasts. With respect to GDP, medical 
doctors, hospital beds, and to some extent, pharmacists, a clear north-south contrast is evident. 
This is also the case for some of the population characteristics, especially the population share of 
elderly, children, and to some extent females, while foreigners seem to cluster over the east coast 
provinces. 
5. RESULTS 
Models for public pharmaceutical expenditure were estimated using multiplicative Cobb-
Douglas type specifications and linearized with log transforms of the explanatory variables. Two 
models—a baseline unexpanded model and another expanded by time and geographical 
coordinates—were estimated. To enhance interpretation, the geographical coordinates H and V 
were mean-adjusted prior to the estimations. All models control for residual temporal 
heterogeneity and dependency as well as spatial spillovers by applying an integrated SUR and 
SAC framework. 
In both specifications, the estimated residual spatial autocorrelation parameter ( ) is 
highly significant. This serves as a Wald test for spatial autocorrelation and indeed shows that 
the control for spatial autocorrelation is necessary. A comparison of the estimated spatial 
autocorrelation parameter of the two specifications further shows that the parameter is smaller 
for the expanded specification. Thus, while expansion may potentially induce spatial spillover, 
this seems not to be the case for the present investigation. Actually, the reduction in the 
magnitude of the spatial autocorrelation parameter when moving from the unexpanded to the 
expanded specification implies that some (although not all) spatial autocorrelation is handled via 
the expansion. Further, spatial autocorrelation persists throughout the period, as Moran tests 
calculated for all variables by year show substantial and persistent spatial autocorrelation in each 
(see Lauridsen et al., 2010). 
Comparing the unexpanded specification (1) and the specification expanded by time (2), 
the importance of accounting for temporal parametric heterogeneity is evident. The LogL, AIC 
and R2 criteria strongly support a preference for the expanded specification. Wald tests support 
both the full expansion as well as the temporal and geographical components. Further, one or 
more expansion coefficients are found to be significant for all variables. Several interpretational 
differences are obtained across the unexpanded and the expanded specifications. While the 
unexpanded specification reports GDP to be insignificant, the expanded specification shows that 
the coefficient of GDP varies considerably across geography. The significantly positive baseline 
coefficient refers to the case T=H=V=0 (i.e., the effect for 1995 for a province located in the 
geographical midpoint of Spain). This should not be directly compared to the corresponding 
coefficient of the unexpanded model (1). To support interpretation of the geographical pattern, 
Figure 3 shows the t-values of the coefficients by provinces (averaged over years). From the 
figure, it is seen that GDP—averaged across years—exerts a significantly positive impact on 
EXP in southern Spain, while a significantly negative impact is exerted in northwestern and 
northeastern Spain. This great variation in the effect of GDP across provinces potentially 
explains the statistical insignificance of the variable in the unexpanded specification. That is, the 
wide  differences  among  the  provinces  cancel  each  other  out  so  that  the net  effect  for the  
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FIGURE 4. Coefficients by Year  
(averaged over provinces) 
      Constant                                 GDP       GDP 
                        BED           MED                                     FEM  
      
                   FOREIGN          OLD    CHILD 
 
“average” province is close to zero. This is confirmed in Figure 4, which shows that the 
“average” province in any year has a GDP effect with a confidence interval spanning zero. 
Likewise, the coefficients for health system characteristics display considerable 
geographic variation. The average of the effect across years of PHARM on EXP is seen to be 
significantly negative in central Spain and significantly positive in the northwest. This contrasts 
with the unexpanded specification (1) of Table 2 where significant positive effects are reported, 
as well as from the evidence in Figure 4 that shows the effect for an “average” province is not 
statistically different from zero. Across years the average effect of BEDS varies from 
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significantly negative in the southeast to significantly positive in a belt of northern provinces, 
except for the northwestern provinces in Galicia and Asturia. This evidence provides a 
modification of the results from the unexpanded specification of Table 2 which reports only a 
marginally significant effect confirmed by Figure 4, where the “average” province has an effect 
that is not significantly different from zero for any year. Regarding MED, a significantly 
negative average effect across years is found for the northern provinces, while a significant 
positive effect is reported for the southern provinces, with the exception of a belt of provinces 
along the southeast coast. The effect of MED differs over time since the coefficient for the time 
interaction term is significant and negative. Consider Figure 4, where the coefficients are shown 
by years (averaged over provinces) together with 95 percent confidence intervals.  The effect of 
MED drops from insignificant to significant, but negative, during the years. 
 
 
TABLE 2.  Seemingly Unrelated Regression Model of Pharmaceutical Expenditures 
 Unexpanded Time and space expanded
 
0  0  T  H  HH  V  VV  HV  
Constant 5.349*** 
(0.546) 
3.945*** 
(0.664) 
-0.048
(0.065) 
0.190
(0.202) 
-0.062
(0.039) 
0.821*** 
(0.227) 
0.276***
(0.083) 
-0.140*
(0.075) 
    
GDP 0.038 
(0.025) 
0.117*** 
(0.032) 
-0.005
(0.005) 
-0.010
(0.007) 
-0.008***
(0.002) 
-0.021*** 
(0.008) 
0.001 
(0.003) 
0.006**
(0.002) 
    
PHARM 0.097*** 
(0.023) 
-0.132*** 
(0.028) 
0.002
(0.003) 
0.001
(0.010) 
0.001
(0.003) 
0.033*** 
(0.010) 
0.016***
(0.004) 
-0.009**
(0.004) 
    
BEDS 0.014* 
(0.008) 
0.018 
(0.016) 
-0.002
(0.002) 
-0.010***
(0.003) 
0.001
(0.001) 
0.021*** 
(0.005) 
-0.006***
(0.002) 
0.007***
(0.002) 
    
MED 0.002 
(0.023) 
0.088*** 
(0.030) 
-0.008*
(0.004) 
-0.025***
(0.008) 
0.005*
(0.002) 
-0.053*** 
(0.009) 
-0.020***
(0.004) 
0.004
(0.004) 
FEM -0.147 
(0.535) 
0.130 
(0.694) 
-0.086*
(0.050) 
0.365*
(0.205) 
-0.224***
(0.047) 
0.816*** 
(0.241) 
0.438***
(0.091) 
-0.104
(0.080) 
FOREIGN -0.005 
(0.005) 
-0.016*** 
(0.005) 
-0.001
(0.001) 
0.004***
(0.001) 
-0.001*
(0.0004) 
0.002 
(0.002) 
0.001 
(0.001) 
0.001
(0.001) 
OLD 0.131*** 
(0.048) 
0.164*** 
(0.060) 
0.001
(0.005) 
-0.011
(0.020) 
0.007*
(0.004) 
-0.004 
(0.027) 
-0.003 
(0.008) 
-0.010
(0.008) 
CHILD -0.022 
(0.026) 
0.096* 
(0.051) 
-0.026***
(0.009) 
0.021*
(0.012) 
-0.013***
(0.003) 
0.015 
(0.011) 
0.016***
(0.005) 
-0.001
(0.004) 
  0.906*** 
(0.013) 
0.758***
(0.041) 
LogL 1367.66 1468.37
AIC -2643.32 -2736.74
R2 0.125 0.798
Wald test 108.40***                      93.02***
Wald test 201.42***   
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Socio-demographic variables exhibit temporal as well as geographical heterogeneity. The 
effect of FEM is, on average across years, significant and negative in provinces in eastern and 
western Spain (especially in Extremadura, Valenciana, and Cataluña) and both significant and 
positive in the Northern ACs. The effects erode over time as indicated by Figure 4. This is 
different evidence than that from the unexpanded specification of Table 2, which reports the 
effect of FEM to be insignificant. The average effect of FOREIGN across provinces is negative 
but grows larger somewhat over time (Figure 4). Interestingly, the average trend in most of the 
country is significant and negative. The exception is the northeastern provinces which reveal no 
effect for FOREIGN. Again, this is different from the message of the unexpanded specification, 
which reports an insignificant effect. The average effect of OLD across provinces is significant 
and positive over time. The average trend effect is likewise positive for most provinces; an 
exception is the very southern provinces and some northeastern ones, where it reveals no effect. 
These findings correspond well with the unexpanded specification, which reports a significant 
and positive effect. Finally, the average effect across provinces of CHILD falls from significant 
and positive to significant and negative over time. The average trend effect is significant and 
negative for a few eastern and western provinces, while it is significant and positive for a few 
northern provinces in the Pais Vasco and Navarra ACs. Again, this contrasts starkly with results 
from the unexpanded specification, which reported an insignificant effect. 
To summarize, the unexpanded specification reports overall average effects that are 
insignificant for several essential variables (GDP, BEDS, MED, FEM, FOREIGN, and CHILD). 
The expanded specification, however, reveals that these overall averages mask substantial 
variation  in   the  effects  across  time (the  case  for  MED  and  CHILD)  and, especially, across 
 
 
Figure 5. Standardized Residuals by Provinces  
(averaged over eight years) 
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provinces (the case for all variables). While the overall average effect for a few variables 
(PHARM and OLD) is significant and positive, it masks substantial variation across provinces, 
spanning significant positive as well as significant negative effects. 
Finally, Figure 5 shows the standardized residuals by provinces (averaged over years). 
The residuals for all but two provinces are within two standard deviations. Thus, spatial variation 
of the pharmaceutical expenditures seems to be captured well by the model. The standardized 
residuals were further inspected for normality using histograms, box plots, and indices of both 
skewness and kurtosis (not reported). This inspection did not reveal deviations from normality. 
Thus, the assumption of normality underlying the Maximum Likelihood estimation seems to be 
adequate. 
6. CONCLUSIONS 
The present study analyzes determinants of public pharmaceutical expenditure in Spain 
and adds to previous knowledge by explicitly modeling temporal as well as geographical 
parametric heterogeneity while controlling for unobserved residual patterns in the form of spatial 
spillover as well as temporal heterogeneity and interdependence. The necessity of accounting for 
the heterogeneous effects of determinants is evident, as the effects of all determinants are subject 
to substantial geographical and/or temporal variations. Especially, the effects of key 
determinants like GDP and health system characteristics are shown to be potentially 
misestimated when parametric heterogeneity is ignored. Thus, the complexity of spatial and 
temporal heterogeneity and spillover is clearly illustrated and the need for further evidence and 
development of modeling practice is demonstrated.  
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